In health news:

🫀 Genetically engineered pig hearts transplanted into dead people. The hearts functioned normally, and there weren’t signs of rejection from the recipients, who were connected to ventilators to keep their body processes functioning semi-regularly, even after death. The two recipients were not able to be organ donors, but were able to participate in whole-body donation for this type of research. - The Verve

🩸 Heavier menstrual bleeding after COVID vaccination as a thing. Except in early 2021, when people started noticing that they had heavier than usual, or unexpected, menstrual bleeding after getting vaccinated against COVID-19. These changes were short-lived, and most people's cycles returned to normal a month or two later. - ScienceAlert

🧠 People with underactive thyroid may face higher dementia risk. Hypothyroidism occurs when the thyroid gland doesn’t make enough thyroid hormones, which can slow metabolism. Symptoms include fatigue, weight gain, and sensitivity to cold. - Futurity

Latest healthtech and biotech deals

The largest from last week:

🇺🇸 Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, announced a Series B funding of $225M.

🇺🇸 CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, closed a $100M Series B round to advance the company’s lead regRNA programs and accelerate the expansion of the company’s regRNA Actuating Platform.

🇺🇸 BigHat Biosciences, a biotechnology company developing antibody therapies for patients using machine learning and synthetic biology, raised a $75M Series B funding round.

🇮🇹 MMI, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75M in Series B financing.

Other notable deals from around the globe:

🇮🇱 ForSight Robotics finished a $55M Series A round for its surgical platform for fully robotic cataract surgery. The platform, named ORYOM, will increase accessibility to ophthalmic surgery procedures worldwide.

🇺🇸 Auron Therapeutics, a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, closed its $48M Series A financing round.

🇺🇸 Centivo, an innovative provider of health plans for self-insured employers built to address health care affordability for employees and their families, received a $30M investment from Morgan Health: the JPMorgan Chase & Co. (NYSE: JPM) business unit focused on improving the quality, equity and affordability of employer-sponsored health care.

Read up on all the latest health deals in Dealroom.co

Tip of the week

🔎 Finding the right investor

The right investors backing can make or break startups. 40% of startups backed by top quartile investors at Seed go on to raise Series A, compared to just 7% for bottom quartile funds.

Dealroom.co's 2022 Investor Rank is the most comprehensive data-driven ranking of the best VC investors in EMEA. We just released a new report, uncovering new insights into the venture capital landscape, underlying data, trends, and methodology.

Download the full report today. 👈

Job opportunities

🇺🇸 VillageMD, a B2B which provides tech and staff support needed for physicians to drive the highest quality clinical results across a population, is hiring 470+ roles including Outreach Specialist and Lead Corporate Recruiter.

🇳🇱 At Dealroom.co, we are hiring for 7 positions including Account Excutive, Graphic Design Intern, and more.

Discover 65K+ jobs openings at healthtech and biotech startups. (login for full results)

Dive in

🎓 Healthtech & Biotech university spinouts

🗺️ Healthtech investment heatmap

🦄 New Healthtech and Biotech unicorns announced in 2021 and 2022YTD

Knowledge partners

Laura Rodriguez

Healthtech Specialist
Dealroom.co

Not a subscriber yet? 

This is Dealroom's weekly health newsletter.  Get more industry-specific intelligence on the evolving world of healthtech and biotech, emerging trends, and game-changing startups. Delivered on Thursdays.